Comparative Pharmacology
Head-to-head clinical analysis: LAZCLUZE versus TRYNGOLZA AUTOINJECTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAZCLUZE versus TRYNGOLZA AUTOINJECTOR.
LAZCLUZE vs TRYNGOLZA (AUTOINJECTOR)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LAZCLUZE (lazertinib) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that irreversibly binds to and inhibits EGFR tyrosine kinase, including mutant forms with T790M resistance mutations and exon 19 deletions, thereby blocking downstream signaling pathways involved in tumor cell proliferation and survival.
Selective inhibitor of protein kinase C theta (PKCθ), reducing T cell activation and cytokine production.
20 mg orally once daily with or without food.
0.5 mg subcutaneously once daily.
None Documented
None Documented
The terminal elimination half-life of Lazcluze is approximately 24-30 hours, supporting once-daily dosing with steady-state achieved within 5-7 days.
Terminal elimination half-life is approximately 21 days (range 14–28 days), consistent with slow clearance from plasma due to target-mediated drug disposition.
Lazcluze is primarily eliminated via biliary excretion into feces, with approximately 70-80% of the administered dose recovered as unchanged drug in feces. Renal elimination accounts for less than 10% of the dose, with less than 1% excreted unchanged in urine.
Primarily eliminated via the reticuloendothelial system; no significant renal or biliary excretion. <1% excreted unchanged in urine.
Category C
Category C
Unknown
Unknown